Celadon Pharmaceuticals (LSE:CEL) Debt-to-Equity : 1.54 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Debt-to-Equity?

Celadon Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.08 Mil. Celadon Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €5.34 Mil. Celadon Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €3.51 Mil. Celadon Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2023 was 1.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Celadon Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

LSE:CEL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.41 Med: 1.07 Max: 29.64
Current: 1.54

During the past 4 years, the highest Debt-to-Equity Ratio of Celadon Pharmaceuticals was 29.64. The lowest was 0.41. And the median was 1.07.

LSE:CEL's Debt-to-Equity is ranked worse than
93.34% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs LSE:CEL: 1.54

Celadon Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Celadon Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Debt-to-Equity Chart

Celadon Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-22.48

29.64

N/A

0.60

Celadon Pharmaceuticals Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial			N/A	-	0.41	0.60	1.54

Competitive Comparison of Celadon Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Celadon Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celadon Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celadon Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Celadon Pharmaceuticals's Debt-to-Equity falls into.

Celadon Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Celadon Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.076	+	5.25)	/	8.825
	=	0.60

Celadon Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.077	+	5.342)	/	3.509
	=	1.54

Celadon Pharmaceuticals (LSE:CEL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Celadon Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines